Multiple Sclerosis

What We Know About Multiple Sclerosis

Symptom domains include spasticity, neuropathic pain, fatigue, bladder dysfunction, and cognitive change. CUP evaluation considerations differ substantially across the MS phenotypes and disease stages.

How TX CUP Addresses Multiple Sclerosis

Low-THC products under the TX CUP for MS patients are evaluated in the context of symptom burden — particularly spasticity, neuropathic pain, and sleep disruption — rather than as disease-modifying therapy. Disease-modifying therapy decisions remain with the treating neurologist.

Our Experience Treating MS Patients Under CUP

Considerations CURT physicians evaluating MS patients typically address:

• Coordination with the patient’s MS specialist or general neurologist
• Drug-interaction screening against disease-modifying therapies (interferons, monoclonal antibodies, S1P modulators, etc.)
• Disease phenotype and current disability level
• Symptom-specific goals — typically spasticity and neuropathic pain
• Cognitive status considerations relevant to dosing and product administration

What to Expect at the Evaluation

A CURT physician evaluating an MS patient typically reviews:

• Neurology notes and MRI history
• Current and prior disease-modifying therapies
• Symptom diary if maintained
• Current symptom-management regimen including baclofen, tizanidine, gabapentinoids, and others
• Functional status

Common Patient Questions About MS and the TX CUP

Last Verified

Next Step

Bookings route through miracleleaftx.com.